The Oral Typhoid Vaccine Market is developing as the global healthcare sector places greater emphasis on preventing infectious diseases. The market is estimated at USD 900 million in 2025 and is forecast to reach USD 2 billion by 2035, advancing at a 7.8% CAGR.

Advances in vaccine formulation and delivery are improving the practicality of oral immunization. New approaches are being explored to enhance vaccine stability and effectiveness, while easier administration can help vaccination programs reach communities where injectable delivery may be more difficult.

Product demand spans live attenuated, inactivated, and conjugate vaccines. Public health programs are a key application, supported by private clinics and pharmaceutical distribution networks that help make vaccines available to travelers, high-risk groups, and communities in endemic areas.

Asia-Pacific is expected to remain a dominant regional market, with the region projected to reach USD 800 million by 2035. North America is also significant, with its market projected to reach USD 500 million by 2035, while Europe, South America, and MEA continue to develop.

Future growth may come from improved vaccine accessibility, combination formulations, advanced delivery methods, and data-driven immunization planning. Stronger government funding and partnerships with health organizations could help expand vaccination coverage and address unmet needs in high-burden areas.